• Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto, more than offset Gleevec/Glivec generic erosion:
    • Cosentyx grew to USD 2.1 billion in 2017, USD 615 million in Q4
    • Entresto grew to USD 507 million in 2017, USD 185 million in Q4
    • Oncology excluding Gleevec/Glivec grew 10% (cc), with 13% (cc) growth in Q4
  • Full year 2017 core[1] operating income was broadly in line with prior year (0% cc …
  • Collaboration aims to help patients worldwide gain access to a range of high-quality, affordable immunology and oncology biologics
  • Partnership will be an important part of Sandoz and Biocon strategy to address the next wave of biosimilar opportunities globally
  • Collaboration will leverage combined strengths of development, manufacturing and commercialization of biosimilars
  • Partnership provides foundation for expansion of portfolio 

Holzkirchen, 18 January 2018 – Sandoz, a Novartis …

  • Adalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1]
  • The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab matches the reference biologic medicine in terms of safety, efficacy and quality[2]-[4]

Holzkirchen, January 16, 2018 – Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), submitted under the 351 (k …

  • Phase I study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine
  • Pegfilgrastim is a long-acting version of the oncology supportive care medicine filgrastim

Holzkirchen, 08 December 2017– Sandoz, a division of Novartis  and the global leader in biosimilars, today announced data demonstrating the pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity of proposed biosimilar pegfilgrastim as compared to the …

  • Sandoz Scientific Standalone Event “Combat Infections to Save Lives” aims at increasing access to information in the field of antibiotic therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA)
  • First event in the field of anti-infectives is utilizing digital platforms to reach healthcare professionals with state-of-art information shared by internationally recognized and trusted experts.

Holzkirchen, November 15, 2017 Sandoz is holding today a Scientific Standalone Event “Combat …

  • Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab
  • Efficacy and safety of biosimilar adalimumab and safety of biosimilar rituximab match reference medicines in multiple-switching and retreatment study respectively 
  • Sandoz biosimilar adalimumab is under EMA review, while EC-approved Sandoz biosimilar rituximab is under review by the FDA

Holzkirchen, November 14, 2017– Sandoz, a Novartis division and the global leader in …

  • Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality
  • Pegfilgrastim is a long-acting version of oncology medicine filgrastim — Sandoz is the European market leader for filgrastim  
  • Sandoz is the global leader in biosimilars, with five biosimilars marketed worldwide and a leading global pipeline, including three biosimilars currently under EMA review

Holzkirchen, October 27, 2017 – Sandoz, a Novartis Division, and the global leader in biosimilars …

  • Net sales grew 2% (cc[1], +2% USD), with growth in all divisions:
    • Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications
    • Entresto (USD 128 million, +138% cc) grew driven by improved access and US sales force expansion
    • Excluding Gleevec/Glivec, Oncology grew 11% (cc)
    • Alcon was up 7%[2] (cc) with strong growth in Surgical and continued growth in Vision Care
    • Sandoz grew 1% (cc) driven by growth outside the US, fully offsetting US price pressure
  • Net sales grew 2% (cc[1], +2% USD), with growth in all divisions:
    • Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications
    • Entresto (USD 128 million, +138% cc) grew driven by improved access and US sales force expansion
    • Excluding Gleevec/Glivec, Oncology grew 11% (cc)
    • Alcon was up 7%[2] (cc) with strong growth in Surgical and continued growth in Vision Care
    • Sandoz grew 1% (cc) driven by growth outside the US, fully offsetting US price pressure
  • 51-week clinical study confirms that  Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile1
  • Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases
  • Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases

 Holzkirchen, September 14, 2017 – Sandoz, a Novartis …